CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Brand Name||Stivarga (CRC)|
|Strength||40 mg tablets|
|Indication||Metastatic Colorectal Cancer|
|Funding Request||The treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy|
|Pre Noc Submission||No|
|NOC Date||March 11, 2013|
|Submission Date||March 22, 2013|
|Submission Deemed Complete||April 8, 2013|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||April 9, 2013|
|Check-point meeting||July 3, 2013|
|pERC Meeting||August 15, 2013|
|Initial Recommendation Issued||August 29, 2013|
|Feedback Deadline ‡||September 13, 2013|
|pERC Reconsideration Meeting||October 31, 2013|
|Final Recommendation Issued||November 15, 2013|
|Notification to Implement Issued||December 2, 2013|
|Therapeutic Area||Metastatic Colorectal Cancer|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.